Status:
TERMINATED
Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)
Lead Sponsor:
Hannover Medical School
Conditions:
Hypertension
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to test whether the addition of inhaled iloprost is safe and effective in patients with idiopathic pulmonary arterial hypertension who are already being treated with the e...
Eligibility Criteria
Inclusion
- IPAH
- \> 3 months treatment with bosentan
- 6 minute walk distance 150 - 425 m
Exclusion
- other forms of pulmonary hypertension
- severe comorbidities
- cotreatment with sildenafil or investigational drugs
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00120380
Start Date
September 1 2004
End Date
May 1 2006
Last Update
August 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hannover Medical School
Hanover, Germany, 30625